OM1 launches dataset to expand Parkinson’s evidence in real world
OM1 has launched a Parkinson’s disease premium dataset to expand real-world evidence on the progression of Parkinson’s…
Articles by Andrea Lobo
Serina-AgeX merger to develop treatment for advanced Parkinson’s
Serina Therapeutics will merge with a wholly-owned subsidiary of AgeX Therapeutics to advance SER-252 (POZ-apomorphine), Serina’s lead treatment…
Lixisenatide may slow disease progression, early data show
Early results from a Phase 2 clinical trial testing lixisenatide, a medication used to treat diabetes, in people with…
Oral therapy GT-02287 shows promise in Parkinson’s mice models
Gain Therapeutics’ GT-02287, an oral investigational therapy for Parkinson’s disease, was found to reduce blood levels of neurofilament…
Walking Tall app goes to bat for people with Parkinson’s disease
People with Parkinson’s disease can learn how to re-train their gait and improve their walking ability with the help…
RaceTrac’s ‘Run for Research’ event on Sept. 16 to support MJFF
RaceTrac is set to revive its “Run for Research” 5K race, scheduled for Sept. 16 at Truist Park in…
Foundation invests $2.8M in 30 grants for innovative research
The Parkinson’s Foundation is investing $2.8 million in 30 research grants to help advance potential new therapies for…
Cannabinoid that might help in Parkinson’s entering Phase 2 trial
Gcanrx soon will open a Phase 2 clinical trial of a neuroprotective cannabinoid treatment that the company expects could…
Minor hallucinations may predict Parkinson’s cognitive decline: Study
The early appearance of minor hallucinations in people with Parkinson’s disease might be a predictor of faster cognitive decline,…
Cell therapy bemdaneprocel safe in advanced Parkinson’s: Phase 1 trial
Treatment with bemdaneprocel (BRT-DA01), BlueRock Therapeutics’s investigational cell-based therapy, was safe and well tolerated among patients with advanced-stage…